Companies › Edgewise Therapeutics
3 active drug programs in 4 registered trials: 4 Phase 2; Cardiovascular, Neurology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sevasemten | – | Phase 2 | Duchenne Muscular Dystrophy | Jan 2027 |
| EDG-15400 Cardiac sarcomere protein modulator | – | Phase 2 | Heart Failure With Preserved Ejection Fraction | Dec 2027 |
| EDG-7500 Cardiac myosin inhibitor | MYBPC3 | Phase 2 | Hypertrophic Cardiomyopathy | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05540860 | Sevasemten | Phase 2 | Duchenne Muscular Dystrophy | Neurology | Jan 2027 |
| NCT06100887 | Sevasemten | Phase 2 | Duchenne Muscular Dystrophy | Neurology | Mar 2027 |
| NCT06347159 | EDG-7500 | Phase 2 | Hypertrophic Cardiomyopathy | Cardiovascular | Dec 2027 |
| NCT07795814 | EDG-15400 | Phase 2 | Heart Failure With Preserved Ejection Fraction | Cardiovascular | Dec 2027 |
Cash of $69m on 2026-09-30; operating cash outflow about $219m a year; runway about 4 months at that burn, to Jan 2027; 1 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 16 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Ever Neuro Pharma AMO Pharma Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) Translational Sciences Gossamer Bio USA
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.